Allumia Ventures

Allumia Ventures, until January 2025 known as Providence Ventures, has spent over a decade proving that healthcare venture capital works differently when your anchor LP is one of the largest health systems in the country. The Seattle-based firm manages 30 investments and 16 successful exits, and 100% of its portfolio has gone on to partner with the firm's LP base—which includes Providence St. Joseph Health and a network of major health systems across the United States.

The spin-out from Providence created a rare structure: an independent VC firm with the strategic network of a health system anchor but the autonomy to invest broadly across the healthcare landscape. Allumia is currently raising its third fund, anchored by a $150 million, 10-year commitment from Providence. For health tech founders, that kind of institutional backing means every portfolio company gets introduced to a customer base that is actively looking for the solutions these companies build.

What makes Allumia distinct is their commercial-stage focus. While many healthcare VCs will write a seed check on a promising thesis, Allumia deploys $5-15M per deal into companies that already have revenue traction, clinical validation, and a clear path to scaling within health systems. The firm's approach centers on partnership rather than just capital—and that philosophy shows up in their board seat preference and their hands-on introduction network.

Allumia invests across three core sectors: digital health, tech-enabled healthcare services, and medtech. Their portfolio spans behavioral health (Lyra Health), substance use disorder treatment (Affect Therapeutics), musculoskeletal care (Livara Health), and a range of clinical workflow and diagnostic tools. Every company in their portfolio solves a concrete problem for health systems or payers, not just for patients in the abstract.

The firm's thesis is straightforward: the best healthcare technology companies are built by founders who have lived the problem, have clinical or operational evidence that their solution works, and can demonstrate a clear route to health system adoption. Allumia's role is to accelerate that adoption by opening doors to the exact health systems that are most likely to become long-term customers.

Allumia Ventures targets what they call 'best-in-class commercial-stage healthcare companies'—businesses that have moved beyond proof-of-concept and into real revenue generation with clinical validation to show for it. Their investment thesis is built on a straightforward conviction: health systems buy from vendors they trust, and trust comes from evidence, not pitches.

The firm's sector focus spans digital health, tech-enabled healthcare services, and medtech. Within those categories, Allumia looks for companies addressing genuine operational or clinical pain points for health systems, payers, and employers. Solutions that improve patient outcomes while reducing cost of care are most attractive—and they expect to see evidence of both claims supported by data.

Allumia typically invests $5-15M per transaction and prefers to lead or co-lead rounds. Their typical investment stage is Series A through Series C, but they focus on companies that already have commercial traction—meaning revenue, not just letters of intent. They do not require portfolio companies to have pre-existing relationships with Providence or other LP health systems, but the expectation is clear: after investment, the firm will leverage its network to open doors.

The firm's Seattle headquarters is complemented by offices in San Francisco, New York City, and Salt Lake City, reflecting their belief that healthcare technology talent and customers are distributed across the country. This geographic presence also helps Allumia source deals across different regional health system ecosystems.

Board participation is part of Allumia's value-add model. The firm prefers to take board seats in portfolio companies, enabling deeper operational involvement and stronger alignment on growth strategy. For founders who want a hands-on investor with real health system connections, Allumia's board approach is a feature, not a constraint.

The firm's 11-year track record with Providence gives them credibility with health system administrators. Portfolio companies frequently cite the warm introductions to procurement and clinical leadership as one of the highest-value parts of the Allumia partnership.

Allumia Ventures has maintained an active investment pace through the recent market correction, demonstrating that their commercial-stage focus provides better deal visibility than earlier-stage peers who have struggled with mark-to-market volatility. The firm led Affect Therapeutics' $26M Series B in late 2025 to scale AI-driven care for substance use and mental health disorders—a category where clinical validation and payer reimbursement pathways are both well-established.

In early 2026, Allumia portfolio company Lyra Health announced a $235M funding round that propelled the behavioral health platform to a $5.58B valuation and included an acquisition for global expansion. Lyra's growth trajectory illustrates what Allumia looks for: a large addressable market (employer-sponsored mental health), measurable clinical outcomes, and a path to substantial revenue without requiring health system procurement cycles.

Allumia is currently raising its third investment fund, anchored by a $150M, 10-year commitment from Providence. The fund structure—longer duration and substantial anchor commitment—reflects the reality that healthcare venture investments take time to reach health system adoption milestones. This capital will allow Allumia to continue writing $5-15M checks in a market where many competitors have pulled back from growth-stage deals.

The portfolio currently spans 30 companies across digital health, medtech, and tech-enabled services. With 16 exits to date, Allumia has demonstrated that their model produces liquidity events—whether through strategic acquisitions by health systems or PE roll-ups in the fragmented healthcare services space.

The spin-out from Providence has also broadened Allumia's investment mandate. As an independent firm, they no longer need to justify every investment purely on strategic alignment with Providence's clinical priorities. The LP base still includes Providence as a cornerstone, but the portfolio can extend into adjacent categories where commercial dynamics align with Allumia's expertise.

Allumia Ventures' portfolio includes 30 healthcare companies that have collectively raised hundreds of millions in follow-on capital. The following are among the most notable based on recent funding activity and market visibility.

Affect Therapeutics is a digital mental health and substance use disorder treatment platform that raised a $26M Series B in late 2025. Allumia led the round, which will be used to scale AI-driven treatment protocols and expand payer relationships. The company's gamified approach to behavioral health has shown clinical efficacy data that resonates with both employers and payers looking for alternatives to traditional therapy models.

Lyra Health is the behavioral health platform that became one of the first unicorns in the employer-sponsored mental health space. With a recent $235M round and $5.58B valuation, Lyra has expanded from executive coaching into comprehensive mental health care including psychiatry, therapy, and substance use treatment. The company's growth reflects the employer demand for scalable mental health benefits that produce measurable outcomes.

Livara Health is addressing the musculoskeletal care market with a value-based care model that aligns incentives between employers, payers, and providers. The company raised a $15M Series B and is deploying the capital to expand its MSK care platform across health plan and employer accounts. Allumia's health system connections have helped Livara access the provider networks needed to deliver its care model.

Other portfolio standouts include Iris Health (behavioral health integration), Praia Health (consumer health engagement), Trilliant Health (analytics), and Press Ganey (patient experience). The common thread across the portfolio is clinical validation and a clear commercial motion—either through health system sales, employer benefits, or payer reimbursement.

Allumia Ventures evaluates potential investments based on commercial traction first and foremost. The firm wants to see revenue—not just pilot LOIs or letters of intent from friendly health systems. Clinical validation through trial data, FDA clearance, or documented patient outcome improvements is the second pillar of their evaluation. Founders should come prepared to show both financial metrics and clinical evidence.

The founding team matters significantly to Allumia. The firm has a strong preference for entrepreneurs who have direct experience with the clinical or operational problem they are solving. A background in healthcare delivery, health system operations, or clinical research signals to Allumia that the team understands the complexity of selling into health systems—and can navigate the stakeholder landscape.

Market size and addressable opportunity are part of every Allumia investment discussion. The firm wants to see large, growing markets where a focused company can achieve meaningful revenue without requiring a decade of health system procurement cycles. Employer-sponsored benefits, outpatient behavioral health, and MSK care are examples of markets with faster commercial cycles.

Competitive positioning is assessed carefully. Allumia looks for companies with durable moats—whether that is proprietary clinical data, exclusive health system partnerships, regulatory barriers (FDA clearance), or technology that materially improves outcomes. The firm is less interested in models with thin differentiation and low switching costs.

Allumia also evaluates the scalability of a company's business model. They prefer companies that can grow revenue without proportional cost increases—a feature of software and platform businesses. Healthcare services companies that require proportional headcount growth to scale revenue receive more scrutiny.

The firm's willingness to take board seats signals they want to be a true partner, not just a check writer. Founders who want a passive investor should look elsewhere. For founders who want operational support, clinical network introductions, and health system sales support, Allumia is among the more partnership-oriented healthcare VCs.

Allumia Ventures receives a high volume of inbound pitches, which means a strategic approach to outreach is essential. The firm prefers warm introductions from their LP network of health system executives, other healthcare investors, or founders who have interacted with their portfolio companies. A recommendation from a clinical advisor or health system leader carries more weight than a cold email from an unknown founder.

The firm's website includes a contact pathway, but Allumia's own FAQ notes that warm introductions from trusted network members are the most effective way to get a meeting. Building relationships with Allumia's portfolio company CEOs is a legitimate path to a warm introduction—these founders can speak directly to what Allumia brings to the table and can advocate on your behalf.

For cold outreach, Allumia's FAQ page makes clear they prefer to lead or co-lead deals and will consider syndicate participation only in specific circumstances. Cold submissions should be concise, clearly articulate the clinical validation and commercial traction to date, and demonstrate why your company fits the firm's sector focus. Lead with revenue data and clinical evidence.

When preparing for a meeting with Allumia, be ready to discuss your revenue trajectory, clinical outcome data, and health system adoption pipeline in detail. The firm will probe the durability of your commercial model and ask hard questions about your path to profitability. They want to see that you understand the full picture—not just the product story.

Follow-up after initial meetings is important. Allumia's investment process typically involves clinical reference checks with health system partners and a thorough review of your regulatory pathway. Maintaining communication and sharing milestone progress helps keep your deal moving through their process.

Even if your current round does not result in an investment, Allumia's relationship orientation means that building a connection with the firm can pay off in future rounds or through portfolio company introductions. The healthcare venture community is tight-knit, and Allumia's partners regularly co-invest with other healthcare VCs who may be a better fit for your current stage.

Allumia Ventures invests in commercial-stage companies, which means they expect founders to have a solid handle on their financials. Revenue metrics, SaaS unit economics, reimbursement pathway clarity, and a credible path to profitability are all topics that will come up in every investment conversation. Early-stage founder mistakes around financial projections can undermine an otherwise strong clinical story.

For healthcare companies specifically, understanding your reimbursement model is non-negotiable. Whether you are billing insurance, selling into health systems, or contracting with employers, Allumia will want to understand your pricing, your collections rate, and your payer mix. These details determine the scalability of your business model.

Founders raising capital for the first time often underestimate the time investment required to manage a fundraise process. Building investor-ready financials, managing due diligence requests, and coordinating with multiple investors takes focus away from running the business. Working with a fractional CFO who understands venture capital and healthcare billing can significantly improve both your presentation quality and your day-to-day operational focus.

Our team has worked with health tech founders at every stage of the fundraising process. From building financial models that show realistic reimbursement pathway assumptions to preparing board-level presentations for institutional investors, we help you present with confidence and clarity.

Financial projections should reflect realistic health system sales cycles and clinical validation timelines. Allumia has seen enough healthcare pitches to spot optimistic assumptions—and they will push back on anything that does not account for the real complexity of health system procurement.

Tracking the right metrics matters for healthcare companies. Allumia wants to see that you understand your clinical outcomes data, your customer acquisition cost, your retention rate, and your net revenue retention. These indicators tell the firm whether your growth is sustainable.

Whether you are preparing to pitch Allumia Ventures or another healthcare-focused investor, professional financials and a clear clinical story will set you apart. Our team has worked with health tech companies at every stage, and we understand what investors look for in financial presentations and due diligence processes.

Exploring other venture capital firms? Our comprehensive collection of VC firm reviews covers hundreds of investors across all stages and sectors.

Each review provides detailed information about investment criteria, portfolio companies, and strategies for securing funding. Whether you are raising a seed round for a digital health startup or a Series C for a medtech platform, our guides help you find the right investor match.

Finding the right investor for your health tech company is one of the most consequential decisions you will make as a founder. The right VC does more than write a check—they open doors, provide operational expertise, and accelerate your path to health system adoption.

Our guides cover the full spectrum of healthcare venture capital, from early-stage seed investors to growth-stage firms like Allumia that focus on commercial traction and revenue scale.